Nateglinide and its metabolites are rapidly and completely eliminated following oral administration. Within 6 hours after dosing, approximately 75% of the administered 14C-nateglinide was recovered in the urine. Eighty-three percent of the 14C-nateglinide was excreted in the urine with an additional 10% eliminated in the feces. Approximately 16% of the 14C-nateglinide was excreted in the urine as parent compound. In all studies of healthy volunteers and patients with Type 2 diabetes , nateglinide plasma concentrations declined rapidly with an average elimination half-life of approximately hours. Consistent with this short elimination half-life, there was no apparent accumulation of nateglinide upon multiple dosing of up to 240 mg three times daily for 7 days.
Anticoagulants: Patients on anticoagulants such as warfarin should be carefully monitored during anabolic steroid therapy as anabolic steroids may increase sensitivity to oral anticoagulants which may require a concomitant reduction in anticoagulant dosage to achieve a desirable prothrombin time (PT). Anticoagulant patients should be monitored regularly during anabolic steroid therapy, particularly during initiation and termination of therapy. Warfarin patients should have INR and PT monitored throughout androgen therapy and warfarin dosages titrated to achieve the desired INR and PT. Such patients should be monitored for occult bleeding.
Stanozolol is the generic name of stanozolol in English , German , French , and Japanese and its INN , USAN , USP , BAN , DCF , and JAN , while stanozololum is its name in Latin , stanozololo is its name in Italian and its DCIT , and estanozolol is its name in Spanish .    Androstanazole , stanazol , stanazolol , and estanazolol are unofficial synonyms of stanozolol.   The drug is also known generically by its former developmental code names NSC-43193 and WIN-14833 .